The molecular and cellular biology of HER2/... [Cancer Treat Res. 2000] - PubMed

Related citations

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. [Oncogene. 1999]
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Oncogene. 1999 Apr 1; 18(13):2241-51.
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. [BMC Cancer. 2006]
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M. BMC Cancer. 2006 Sep 15; 6:225. Epub 2006 Sep 15.
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". [Clin Transl Oncol. 2006]
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA, Vázquez-Martín A, Ropero S, Colomer R, Lupu R. Clin Transl Oncol. 2006 Nov; 8(11):812-20.
Review Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. [Cancer Biother Radiopharm. 1999]
Review Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.
Dillman RO. Cancer Biother Radiopharm. 1999 Feb; 14(1):5-10.
Review Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. [Semin Oncol. 2001]
Review Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN. Semin Oncol. 2001 Dec; 28(6 Suppl 18):43-7.

See reviews... See all...

Cited by 13 PubMed Central articles

Autophagy: friend or foe in breast cancer development, progression, and treatment. [Int J Breast Cancer. 2011]
Autophagy: friend or foe in breast cancer development, progression, and treatment.
Berardi DE, Campodónico PB, Díaz Bessone MI, Urtreger AJ, Todaro LB. Int J Breast Cancer. 2011; 2011:595092. Epub 2011 Sep 8.
Hunk is required for HER2/neu-induced mammary tumorigenesis. [J Clin Invest. 2011]
Hunk is required for HER2/neu-induced mammary tumorigenesis.
Yeh ES, Yang TW, Jung JJ, Gardner HP, Cardiff RD, Chodosh LA. J Clin Invest. 2011 Mar; 121(3):866-79.
Robust unmixing of tumor states in array comparative genomic hybridization data. [Bioinformatics. 2010]
Robust unmixing of tumor states in array comparative genomic hybridization data.
Tolliver D, Tsourakakis C, Subramanian A, Shackney S, Schwartz R. Bioinformatics. 2010 Jun 15; 26(12):i106-14.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The molecular and cellular biology of HER2/neu gene amplification/overexpression...
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Cancer Treat Res. 2000 ;103:57-75.

PubMed
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell...
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.
Nat Cell Biol. 2007 Feb ;9(2):201-9. Epub 2006 Dec 24 .

PubMed
Do the cholesterol-lowering properties of statins affect cancer risk?
Do the cholesterol-lowering properties of statins affect cancer risk?
Trends Endocrinol Metab. 2008 May-Jun ;19(4):113-21. Epub 2008 Mar 20 .

PubMed
Ductal lavage findings in women with known breast cancer undergoing mastectomy.
Ductal lavage findings in women with known breast cancer undergoing mastectomy.
J Natl Cancer Inst. 2004 Oct 20 ;96(20):1510-7.

PubMed
Current and future technologies for breast cancer imaging.
Current and future technologies for breast cancer imaging.
Breast Cancer Res. 2001 ;3(1):14-6.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

Source

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Other Literature Sources

Medical

Libraries

Supplemental Content

Related citations

Cited by 13 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information